Therapeia Pharmaceuticals

What Therapeia Pharmaceuticals does

Therapeia Pharmaceuticals Pvt. Ltd is a privately held Indian generic pharmaceutical company incorporated in 2012 and headquartered at Krishnakeval Township, NIBM Road, Kondhwa, Pune 411048. The company manufactures and markets a finished-dosage-formulation portfolio that spans hematinics under the HEMTHERAPY brand (syrup, 30mg and 100mg tablets built on ferrous ascorbate with folic acid, pyridoxine, and methylcobalamin), anti-ulcerants (DPPI, a rabeprazole 20mg + domperidone 30mg sustained-release combination), anti-infectives (Inmixo, an ofloxacin + ornidazole film-coated tablet), anti-inflammatory analgesics (FNP, aceclofenac + paracetamol), oral care (Orate Gel, containing choline salicylate, benzalkonium chloride, and lignocaine), and nutraceuticals (Mivitlo, a multi-vitamin, multi-mineral antioxidant tablet). Therapeia states it applies quality control at raw material, in-process, and finished product stages and highlights sustained-release and enteric-coated pellet technologies as differentiators on its combination products.

The business operates a sales-led go-to-market: products are promoted through a field force of Medical Representatives who call on doctors, run medical information symposia, and aim to generate prescriptions and brand equity across assigned territories. Commercial reach today is limited to parts of three Indian states — Maharashtra (including Pune, Solapur, and Ichalkaranji), Andhra Pradesh, and Karnataka — with the company publicly stating it is "in the process of expanding our marketing and distribution channels in India." End customers are healthcare providers and patients; SKU-level pricing is not disclosed, and the portfolio is positioned as affordable generics rather than specialty or innovation-driven products. Marketing channels are the company website (corporate presence), social media (Facebook, LinkedIn), and field-engagement activities at the territory level.

Therapeia carries no disclosed external investors, no parent or subsidiary structure, no M&A history, no strategic partnerships, no patents or trademarks, no awards, and no management team disclosures beyond two named directors (Ilyas Ismail Tambe and Afzalmohamad Moinuddin Peerzade). Revenue figures are not published, and the corporate website footer copyright ends at 2014, indicating limited recent digital investment. The company is operationally active but small-scope: 51–100 employees, single-country distribution, and a generic-portfolio competitive position in a highly fragmented Indian pharma market.

Name

Therapeia Pharmaceuticals

Legal name

Therapeia Pharmaceuticals Pvt. Ltd

Website

https://therapeiapharma.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Therapeia Pharmaceuticals is a Pune-based, privately held Indian generic pharmaceutical company incorporated in 2012 that manufactures and markets formulations in hematinics, anti-ulcerants, anti-infectives, pain management, oral care, and nutraceuticals, sold through a Medical Representative field force to doctors and patients across three Indian states.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic ANDA/Regulatory Affairs & Submissions (HLAIABAJ)

Keywords

• Generic pharmaceutical formulations
• Iron deficiency anemia therapy
• Anti-ulcerant medications
• Anti-infective formulations
• Nutraceutical supplements

Headquarters

HQ city

Pune

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from manufacturing and marketing generic pharmaceutical products including hematinics, anti-ulcerants, anti-infectives, pain relief medications, and nutraceuticals. Products sold through distribution network across Indian states.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Therapeia Pharmaceuticals manufactures and markets branded generic pharmaceutical formulations including hematinics, anti-ulcerants, anti-infectives, anti-inflammatory analgesics, oral care gels, and nutraceuticals. The company focuses on formulations with improved bioavailability (ferrous ascorbate) and sustained-release drug delivery, distributing its products in India through a field force of Medical Representatives who engage doctors and healthcare providers to drive prescriptions.

Product overview

Therapeia Pharmaceuticals is a pharmaceutical company headquartered in Pune, India, incorporated in 2012. The company manufactures and markets a portfolio of pharmaceutical products across multiple therapeutic categories including hematinics (HEMTHERAPY line of syrup and tablets), anti-ulcerants (DPPI), anti-diarrheals (Inmixo), anti-inflammatory/pain relief (FNP), oral care (Orate Gel), and nutraceuticals (Mivitlo). The company operates primarily in Maharashtra, Andhra Pradesh, and Karnataka with expansion plans across India. Products are distributed through medical representatives targeting doctors and healthcare facilities.

Differentiator

Problem solved

Functional benefit

Brands

• Hemtherapy: Iron supplement product line including syrup and tablets (30mg, 100mg) for treating iron deficiency anemia.
• DPPI
• Inmixo
• FNP
• Orate gel
• Mivitlo

Products and services

• HEMTHERAPY Syrup Hematinic syrup providing complete formula for faster rise in hemoglobin; contains ferrous ascorbate (30mg elemental iron per 5ml), folic acid, pyridoxine, and methylcobalamin for treatment of iron deficiency anemia. Targeted at patients (especially pediatric) requiring iron supplementation.
• HEMTHERAPY 100mg Tablet Iron supplement tablet containing ferrous ascorbate providing 100mg elemental iron, folic acid, methylcobalamin, and pyridoxine; indicated for pregnancy anemia and increased iron demands.
• HEMTHERAPY 30mg Tablet Iron deficiency anemia treatment tablet combining ferrous ascorbate (30mg elemental iron) with folic acid, methylcobalamin, and pyridoxine for superior and complete iron deficiency anemia treatment.
• DPPI Anti-ulcerant capsule combining Rabeprazole 20mg (PPI for faster onset of action) with Domperidone 30mg (sustained-release pro-kinetic) for once-daily treatment of GERD, dyspepsia, and gastritis.
• Inmixo Anti-diarrheal film-coated tablet combining Ofloxacin 200mg with Ornidazole 500mg for treatment of gastrointestinal infections, mixed infections, diarrhea, dysentery, and post-surgical infections.
• FNP Anti-pyretic and anti-inflammatory film-coated tablet combining Aceclofenac 100mg with Paracetamol 350mg to provide complete pain relief by counteracting both central and peripheral pain mechanisms, with minimal GI side effects.
• Orate Gel Oral gel containing Choline Salicylate 8.7% w/w, Benzalkonium Chloride 0.01% w/w, and Lignocaine 2% w/w for faster pain relief in oral ulcers, aphthous ulcers, and gum infections.
• Mivitlo Nutraceutical anti-oxidant multi-vitamin and multi-mineral film-coated tablet containing vitamins A, B-complex, C, D3, E, zinc, magnesium, manganese, copper, selenium, chromium, and other essential nutrients for boosting immunity and overall body development.

Quantifiable outcome

• Faster rise in hemoglobin with ferrous ascorbate-based hematinic formulations
• +2 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Alkem Laboratories: Mid-sized Indian pharma with strong presence in anti-infectives, GI, and vitamins/nutraceuticals, competing in the same sub-therapeutic categories Therapeia addresses.
• Indoco Remedies: Mid-sized Indian pharma with strengths in formulations, anti-infectives, and stomatologicals (oral care) — directly aligned with several of Therapeia's product lines.
• Mankind Pharma: India's largest pharma company by prescription volume; directly comparable as a branded-generic, field-sales-driven player operating across hematinics, GI, anti-infectives, and pain — the same therapeutic categories Therapeia targets.
• Unichem Laboratories: Mid-cap Indian pharma focused on formulations across cardiology, GI, and vitamins; closest in size, scope, and field-sales GTM to Therapeia.
• Macleods Pharmaceuticals: Indian pharma with broad presence in anti-infectives, GI, and anti-inflammatory segments; sells via a medical-representative model similar to Therapeia's GTM.

Broad incumbents

• Ipca Laboratories: Established Indian pharma with strong anti-infective and pain portfolios; competes with Therapeia on Inmixo and FNP equivalents.
• Torrent Pharmaceuticals: Large Indian branded-generic player; overlaps with Therapeia in GI and hematinic categories across India's major markets.
• Glenmark Pharmaceuticals: Diversified Indian pharma with substantial dermatology, respiratory, and GI presence; a relevant broad incumbent for branded generics in India's domestic market.
• Cipla: One of India's largest incumbent pharma companies with extensive portfolios in respiratory, GI, and anti-infectives; competes broadly with Therapeia across multiple of its categories.
• Dr. Reddy's Laboratories: Major Indian generics manufacturer; overlaps with Therapeia in branded generics for GI, pain, and anti-infectives at national and global scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/therapeiapharma
• LinkedInlinkedin.com/company/therapeia-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Therapeia Pharmaceuticals